Taxonomic group: bacteria / Proteobacteria
(Phylum: Proteobacteria)
Host organism: Homo sapiens
Associated disease: typhoid fever [ICD11:
1A07 
, ICD11:
XN4AM 
];
infection due to Salmonella typhi [ICD11:
XN4AM 
]
NCBI PubMed ID: 10534182Publication DOI: 10.1007/s100960050361Journal NLM ID: 8804297Publisher: Berlin: Springer
Institutions: Pasteur Mérieux MSD, 8 rue Jonas Salk, F-69007 Lyon, France, FR, Pasteur Mérieux Connaught, 51 Avenue Leclerc, F-69007 Lyon, France, Pasteur Mérieux Connaught, 3 Avenue Pasteur, F-92430 Marnes La Coquette, France
Typhoid fever remains an important health threat in many parts of the world, with an estimated 16 million cases and 600,000 deaths occurring each year. The emergence of Salmonella typhi strains multiply resistant to antibiotics has complicated the treatment of this disease. Field experience of 8 years shows that a vaccine composed of purified Vi capsular polysaccharide of Salmonella typhi, given as a single intramuscular or deep subcutaneous injection, has consistent immunogenicity and efficacy. Side effects, based on reports since 1989, are infrequent and mild. Furthermore, the Vi vaccine may be administered simultaneously with other common "travel" vaccines, at two different sites of injection, without affecting immunogenicity and tolerability. This review presents an update of the development and clinical experience with the Salmonella typhi Vi polysaccharide vaccine (Typhim Vi; Pasteur Merieux Connaught, France).
Salmonella typhi, vaccine, polysaccharide vaccine, Vi capsular polysaccharide
Structure type: homopolymer
Location inside paper: p.611, fig.1
Trivial name: Vi-antigen, Vi antigen, Vi polysaccharide, Vi-antigen (glycotope)
Compound class: CPS
Contained glycoepitopes: IEDB_144984,IEDB_164179,IEDB_164180,IEDB_164181
Comments, role: the review summarizes the development and experience with the Vi vaccine
NCBI Taxonomy refs (TaxIDs): 90370Reference(s) to other database(s): GTC:G67538LH
Show glycosyltransferases
There is only one chemically distinct structure: